Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 263

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial

Open access
Biswal, Shibadas, Borja-Tabora, Charissa, Martinez Vargas, Luis, Velásquez, Hector, Theresa Alera, Maria, Sierra, Victor, Johana Rodriguez-Arenales, Edith, Yu, Delia, Wickramasinghe, V Pujitha, Duarte Moreira, Edson, Fernando, Asvini D, Gunasekera, Dulanie, Kosalaraksa, Pope, Espinoza, Felix, López-Medina, Eduardo, Bravo, Lulu, Tuboi, Suely, Hutagalung, Yanee, Garbes, Pedro, Escudero, Ian, Rauscher, Martina, Bizjajeva, Svetlana, LeFevre, Inge, Borkowski, Astrid, Saez-Llorens, Xavier, Wallace, Derek, Concepción, Alys, Villarreal, Ana Cecilia, Fernando, Asvini, Borja-Tabora, Charissa, Sirivichayakul, Chukiat, Yu, Delia, Gunasekera, Dulanie, López-Medina, Eduardo, Rodriguez-Arenales, Edith Johanna, Moreira, Edson Duarte, Espinoza, Felix, Velásquez, Hector, Reynales, Humberto, Luz, Kleber, Jimeno, Jose, Fernando, LakKumar, Bravo, Lulu, Vargas, Luis Martinez, Rivera, Luis, Alera, Maria Theresa, Manacharoen, Onanong, Lopez, Pio, Kosalaraksa, Pope, Wickramasinghe, V. Pujitha, Dietze, Reynaldo, da Cunha, Rivaldo Venâncio, Watanaveeradej, Veerachai, Sierra, Victor, Saez-Llorens, Xavier, Biswal, Shibadas, Brose, Manja, Rauscher, Martina, Bizjajeva, Svetlana, LeFevre, Inge, Borkowski, Astrid, Wallace, Derek, Escudero, Ian, Moss, Kelley, Garbes, Pedro, Meyer, Seetha, Hutagalung, Yanee, Tuboi, Suely, Tricou, Vianney·2020·The Lancet

Abstract

BACKGROUND A substantial unmet need remains for safe and effective vaccines against dengue virus disease, particularly for individuals who are dengue-naive and those younger than 9 years. We aimed to assess the efficacy, safety, and immunogenicity of a live attenuated tetravalent dengue vaccine (TAK-003) in healthy children aged 4-16 years. METHODS We present data up to 18 months post-vaccination from an ongoing phase 3, randomised, double-blind trial of TAK-003 in endemic regions of Asia and Latin America (26 medical and research centres across Brazil, Colombia, Dominican Republic, Nicaragua, Panama, Philippines, Sri Lanka, and Thailand). Healthy children aged 4-16 years were randomly assigned 2:1 (stratified by age and region) to receive two doses of TAK-003 or two doses of placebo, 3 months apart. Investigators, participants and their parents or guardians, and sponsor representatives advising on trial conduct were masked to trial group assignments. Participants presenting with febrile illness were tested for virologically confirmed dengue (VCD) by serotype-specific RT-PCR. In timeframes beginning 30 days post-second dose, the primary endpoint (overall vaccine efficacy) was assessed in the first 11 months, and the secondary endpoints (efficacy by baseline serostatus, serotype, hospitalised dengue, and severe dengue) in the first 17 months. This study is registered with ClinicalTrials.gov, NCT02747927. FINDINGS 20 099 participants were randomly assigned and vaccinated between Sept 7, 2016, and Aug 18, 2017; 19 021 (94·6%) were included in the per protocol analysis, and 20 071 (99·9%) in the safety set. The primary endpoint was achieved with an overall vaccine efficacy of 80·2% (95% CI 73·3 to 85·3; 61 cases of VCD in the TAK-003 group vs 149 cases of VCD in the placebo group). In the secondary endpoint assessment timeframe, an overall vaccine efficacy of 73·3% (95% CI 66·5 to 78·8) was observed. Analysis of secondary endpoints showed efficacies of 76·1% (95% CI 68·5 to 81·9) in individuals who were seropositive at baseline, 66·2% (49·1 to 77·5) in individuals who were seronegative at baseline, 90·4% (82·6 to 94·7) against hospitalised dengue, and 85·9% (31·9 to 97·1) against dengue haemorrhagic fever. Efficacy varied by individual serotypes (DENV 1, 69·8% [95% CI 54·8 to 79·9]; DENV 2, 95·1% [89·9 to 97·6]; DENV 3, 48·9% [27·2 to 64·1]; DENV 4, 51·0% [-69·4 to 85·8]). Cumulative rates of serious adverse events were similar in TAK-003 (4·0%) and placebo (4·8%) recipients, and were consistent with expected medical disorders in the study population. Infection was the most frequent reason leading to serious adverse events. 20 participants (<0·1% of the safety set) were withdrawn from the trial due to 21 adverse events by the end of part two; 14 of these participants received TAK-003 and six received placebo. INTERPRETATION TAK-003 was well tolerated and efficacious against symptomatic dengue in children regardless of serostatus before immunisation. Vaccine efficacy varied by serotype, warranting continued follow-up to assess longer-term vaccine performance. FUNDING Takeda Vaccines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(20)30414-1

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 263

Metadata

Authors
Biswal, S., Borja-Tabora, C., Martinez Vargas, L., Velásquez, H., Theresa Alera, M., Sierra, V., Johana Rodriguez-Arenales, E., Yu, D., Wickramasinghe, V. P., Duarte Moreira, E., Fernando, A. D., Gunasekera, D., Kosalaraksa, P., Espinoza, F., López-Medina, E., Bravo, L., Tuboi, S., Hutagalung, Y., Garbes, P., Escudero, I., Rauscher, M., Bizjajeva, S., LeFevre, I., Borkowski, A., Saez-Llorens, X., Wallace, D., Concepción, A., Villarreal, A. C., Fernando, A., Borja-Tabora, C., Sirivichayakul, C., Yu, D., Gunasekera, D., López-Medina, E., Rodriguez-Arenales, E. J., Moreira, E. D., Espinoza, F., Velásquez, H., Reynales, H., Luz, K., Jimeno, J., Fernando, L., Bravo, L., Vargas, L. M., Rivera, L., Alera, M. T., Manacharoen, O., Lopez, P., Kosalaraksa, P., Wickramasinghe, V. P., Dietze, R., da Cunha, R. V., Watanaveeradej, V., Sierra, V., Saez-Llorens, X., Biswal, S., Brose, M., Rauscher, M., Bizjajeva, S., LeFevre, I., Borkowski, A., Wallace, D., Escudero, I., Moss, K., Garbes, P., Meyer, S., Hutagalung, Y., Tuboi, S., & Tricou, V.
Venue
The Lancet
Publisher
Elsevier BV
Published
2020-05
Volume
395
Issue
10234
Pages
1423-1433
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3011429008
Cited by
263
References
22
FWCI
23.75
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(20)30414-1
The paper
Biswal, S., Borja-Tabora, C., Martinez Vargas, L., Velásquez, H., Theresa Alera, M., Sierra, V., Johana Rodriguez-Arenales, E., Yu, D., Wickramasinghe, V. P., Duarte Moreira, E., Fernando, A. D., Gunasekera, D., Kosalaraksa, P., Espinoza, F., López-Medina, E., Bravo, L., Tuboi, S., Hutagalung, Y., Garbes, P., . . . Tricou, V. (2020). Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(20)30414-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.